Our preliminary proteomic analysis revealed a significant upregulation of ARL4C in CRC clinical tissues exhibiting oxaliplatin treatment failure, suggesting its potential involvement in resistance mechanisms. Here, ARL4C is linked to colorectal carcinoma.